3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Multiple Myeloma
363
Precursor Cell Lymphoblastic Leukemia-Lymphoma
89
Leukemia
61
Neoplasms, Plasma Cell
60
Lymphoma
59
Recurrence
52
Neoplasms
34
Vomiting
33
Lymphoma, Non-Hodgkin
32
Immunoglobulin Light-chain Amyloidosis
27
Lymphoma, Mantle-Cell
26
Burkitt Lymphoma
26
Nausea
22
Lymphoma, Large B-Cell, Diffuse
21
Leukemia, Lymphocytic, Chronic, B-Cell
21
Waldenstrom Macroglobulinemia
19
Prostatic Neoplasms
19
Lymphoma, Follicular
18
Hodgkin Disease
18
Neoplasm Metastasis
14
Breast Neoplasms
14
Amyloidosis
12
Lymphoma, B-Cell, Marginal Zone
11
Leukemia, Myeloid, Acute
11
Carcinoma, Non-Small-Cell Lung
11
Ovarian Neoplasms
9
Lymphoma, Large-Cell, Immunoblastic
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell, Cutaneous
8
Colonic Neoplasms
8
Interventions
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Systemic Inflammatory Response Syndrome
×
Dexamethasone
×
Clear all
NCT03125941
2019-12-02
DEX-MAS
Rigshospitalet, Denmark
Phase 4
Completed
130 enrolled
20 charts